123I-iomazenil whole-body imaging to detect hepatic carboxylesterase drug-metabolizing enzyme activity by A Mizutani, et al.
123I-iomazenil whole-body imaging to detect hepatic carboxylesterase drug-
metabolizing enzyme activity  
 
Asuka Mizutani, MS 1,2, Masato Kobayashi, PhD3, Ken-ichi Fujita, PhD4, Kotaro 
Takahashi5, MS, Tsuzumi Hokama, BS5, Hiroaki Takasu, BS5, Kodai Nishi, PhD6, 
Ryuichi Nishii, MD, PhD7, Naoto Shikano, PhD8, Kazuki Fukuchi, MD, PhD1, Keiichi 
Kawai, PhD5,9,* 
 
1 Division of Medical Technology and Science, Department of Medical Physics and 
Engineering, Course of Health Science, Graduate School of Medicine, Osaka University, 
Osaka, Japan 
2 Department of Radiology, Kanazawa University Hospital, Kanazawa, Japan 
3 Wellness Promotion Science Center, College of Medical, Pharmaceutical and Health 
Sciences, Kanazawa University, Kanazawa, Japan 
4 Institute of Molecular Oncology, Showa University, Tokyo, Japan 
5 School of Health Sciences, College of Medical, Pharmaceutical and Health Sciences, 
Kanazawa University, Kanazawa, Japan 
6 Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki 
University, Nagasaki, Japan 
7 Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan 
8 Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, 
Ibaraki, Japan 
9 Biomedical Imaging Research Center, University of Fukui, Fukui, Japan 
 
Address correspondence and requests for reprints to: 
Keiichi Kawai, PhD 
School of Health Sciences, College of Medical, Pharmaceutical and Health Sciences, 
Kanazawa University  
5-11-80 Kodatsuno, Kanazawa 920-0942, Japan 
Tel: +81-76-265-2527; Fax: +81-76-234-4366 
E-mail: kei@mhs.mp.kanazawa-u.ac.jp 
 
Abstract  
Objectives: Drugs are mainly metabolized by hepatic enzymes, the activity of 
which can differ between individuals. Although it is ideal to measure the 
hepatic clearance of liver-targeted drugs in individualized medicine, blood 
enzyme tests typically measure metabolic drug clearance in the entire body, 
and not just in the liver. We investigated whether 123I-iomazenil imaging can 
directly assess and quantify the activity of hepatic drug- metabolizing 
enzymes.  
Methods: Hepatic enzymes that metabolize 123I-iomazenil were identified by 
thin-layer chromatography in mouse liver homogenates with bis(4-
nitrophenyl) phosphate (BNPP) inhibitor for carboxylesterase enzymes and 
nicotinamide adenine dinucleotide phosphate (NADPH) generator for 
cytochrome P450 enzymes. Whole-body images of mice were acquired using 
123I-iomazenil with and without BNPP, and the distribution was also obtained. 
The metabolism of 123I-iomazenil in the blood, liver, gall bladder, and bladder 
was investigated by thin-layer chromatography. 
Results: From the in-vitro metabolism of 123I-iomazenil using BNPP, the 
enzyme converting 123I-iomazenil to 123I-R-COOH was identified as 
carboxylesterase, and that converting 123I-iomazenil to M2 was identified as 
cytochrome P450 in experiments with and without an NADPH generator. The 
biological distribution and whole-body imaging showed increased 
accumulation in the liver of mice administered BNPP compared with normal 
mice, but decreased levels in the gall bladder and small intestine. The main 
fraction in bile and urine was 123I-R-COOH, with two unknown metabolites 
(M1 and M2), 123I−, and 123I-iomazenil also being present. 
Conclusions: 123I-iomazenil whole-body imaging has good possibility of direct 
measurement of hepatic carboxylesterase activity as accumulation of 123I-R-
COOH in the gall bladder through bile and in the bladder through urine.  
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Introduction  
Drugs are mainly metabolized in vivo by hepatic enzymes, the activity 
of which can differ between individuals [1,2], because of various factors such 
as genetic polymorphisms. This can lead to therapeutic failure, adverse 
effects, or drug toxicity [3–5]. The liver harbors many hepatic drug-
metabolizing enzymes including cytochrome P450 (CYP) [6] and 
carboxylesterase [7,8]. Measuring the activity and capacity of hepatic drug- 
metabolizing enzymes could be useful for determining the best drug and 
optimal dose to use in individualized medicine. Although it is ideal to measure 
the hepatic clearance of liver-targeted drugs [9] in individualized medicine, 
blood enzyme tests typically measure metabolic drug clearance in the entire 
body, and not just in the liver [3]. The in-vitro–in-vivo extrapolation method 
has been applied with human hepatic samples to measure metabolic drug 
clearance [10], but hepatic cells in vitro do not perfectly mimic cells in 
complete organs. 
Nuclear medicine imaging could potentially be used to directly detect 
and quantify the activity of drug-metabolizing enzymes in metabolic drug 
clearance. To achieve this, however, the following conditions must be met: (i) 
a radiopharmaceutical accumulates in a metabolic organ, (ii) the 
radiopharmaceutical is metabolized by a specific drug-metabolizing enzyme 
and the radioactive metabolite transfers from the metabolic organ to an 
excretory organ, (iii) accumulation in the excretory organ can be visualized 
and quantitated. Our previous study showed that 123I-N-isopropyl-p-
iodoamphetamine (123I-IMP), which is clinically used to measure cerebral 
blood flow in single-photon emission computed tomography (SPECT) imaging, 
[11–14] is mainly metabolized and converted to 123I-p-iodoamphetamine in 
the liver by the specific enzyme CYP2C19 in humans [13]. We reported that 
chromatographic analysis of blood samples, not whole-body imaging, can be 
used to measure CYP2C19 activity in the human liver using 123I-IMP, but this 
methodology also measures metabolic drug clearance in the entire body. 
Although whole-body imaging is a noninvasive method for the clinical 
analysis of enzyme activity, it is difficult to directly detect and quantify 
CYP2C19 activity in 123I-IMP whole-body imaging, because small amounts of 
administered 123I-IMP are converted to 123I-p-iodoamphetamine, a hepatic 
metabolite, by hepatic CYP2C19, as shown in our previous study [13]. 
123I-Iomazenil (123I-IMZ) has already been used for neural receptor 
scintigraphy in clinical examinations [15] and is primarily metabolized to a 
carboxylic acid (123I-R- COOH), with deiodination (123I−), limited conjugation 
(123I-R-COOH-Glc), and oxidation (123I-R′-CH2COOH) (see Supplementary 
Fig., Supplemental digital content 1, http://links.lww.com/NMC/A132, which 
shows metabolic pathway of 123I-IMZ) [16]. 123I-IMZ accumulates in the bile, 
urine, and feces by enterohepatic and renal routes in both small animals [16] 
and humans [17–19]. Thus, 123I-IMZ is a possible candidate for direct 
detection and quantification of the activity of drug-metabolizing enzymes 
based on the above necessary conditions. The objective of this study was to 
investigate whether 123I-IMZ whole-body imaging enables detection and 
quantification of hepatic drug-metabolizing enzyme activity. 
 
Methods  
Materials  
Acetate, chloroform, dipotassium hydrogen phosphate, EDTA 
disodium salt, glucose-6-phosphate, magnesium chloride, potassium 
dihydrogen phosphate, and sodium acetate were purchased from Nacalai 
Tesque (Kyoto, Japan). Bis(4-nitrophenyl) phosphate (BNPP) was purchased 
from Tokyo Chemical Industry (Tokyo, Japan). β-NADP+ and glucose-6-
phosphate dehydrogenase (G6PD) were purchased from Oriental Yeast 
(Osaka, Japan). 125I-IMZ was supplied by and 123I-IMZ was purchased from 
Nihon Medi-Physics (Chiba, Japan).  The radiochemical purity of 123I-IMZ 
and 125I-IMZ was more than 98 and 95%, respectively. All of the other 
reagents and chemicals were of analytical or high-performance liquid 
chromatography grade. 
Metabolism of 123I-IMZ in vitro  
To prepare the pooled liver homogenates, three 6-week-old male ddY 
mice (Japan SLC, Tokyo, Japan) were euthanized under anesthesia using 
isoflurane.  The livers were removed and weighed. After addition of Krebs-
Ringer phosphate buffer (pH = 7.4), the pooled livers were homogenized with 
an ultrasonic homogenizer (SONIFIER250; Branson, St. Luis, Missouri, 
USA), and the protein content was determined according to the bicinchoninic 
acid method [20]. For analysis of carboxylesterase-mediated metabolism, 
BNPP was used as a specific and hepatic carboxylesterase inhibitor [21]. 
Carboxylesterase-mediated metabolism of 123I-IMZ was examined in a 
mixture consisting of 100 mmol/l sodium potassium phosphate buffer  (pH = 
7.4), 50 µmol/l EDTA disodium salt, the nicotinamide adenine dinucleotide 
phosphate (NADPH)-generating system (0.5 mmol/l β-NADP+, 5 mmol/l  
MgCl2, 5 mmol/l glucose-6-phosphate, and 1 U/ml glucose-6-phosphate 
dehydrogenase), BNPP (0.1, 1, 10, 100 µmol/l), and 1000 µg protein/20 µl 
pooled mouse liver homogenates in a final volume of 250 µl. A mixture without 
BNPP was used as the control. The sample was incubated at 37°C for 60 min 
with gentle shaking. The reaction was stopped by adding 100 µl ethanol. 
Subsequently, the mixture was centrifuged for 5 min at 18 000g, and the 
supernatant was analyzed by thin-layer chromatography (TLC) using 
chloroform/ acetate/H2O at a ratio of 65 : 35 : 5 [22]. For analysis of CYP-
mediated metabolism, NADPH was used as an energy source [6]. NADPH-
dependent metabolism of 123I-IMZ was examined in an incubation mixture 
consisting of 100 mmol/l sodium potassium phosphate buffer (pH = 7.4), 50 
µmol/l EDTA disodium salt, NADPH generator, and 1000 µg protein/20 µl 
pooled mouse liver homogenates in a final volume of 250 µl. A mixture without 
NADPH generator was used as the control. The sample was incubated at 37°C 
for 60 min with gentle shaking. The reaction was stopped by adding 100 µl 
ethanol. Subsequently, the mixture was centrifuged for 5 min at 18 000g. The 
metabolites in each sample were analyzed by TLC. The supernatant was 
spotted onto a silica gel TLC plate 60 F254 (Merck, Darmstadt, Germany). 
The TLC plate and the TLC spots were developed using chloroform/acetate/ 
H2O at a ratio of 65 : 35 : 5 [22]. After development and complete drying, the 
TLC plates were cut into 21 fractions, and the radioactivity associated with 
each fraction was quantified using a γ-ray counter (AccuFLEXγ 7000; Aloka, 
Tokyo, Japan). The fractional ratios of 123I−, 123I-R-COOH, 123I-IMZ, and other 
metabolites were calculated by dividing the radioactive counts for each 
fraction by the total radioactivity count. 
 
Whole-body imaging and biological distribution in normal mice using 123/125I-
IMZ  
Animal studies were approved by the Animal Care Committee at 
Kanazawa University (Kanazawa, Japan) and were conducted in accordance 
with international standards for animal welfare and institutional guidelines. 
All of the acquisitions were performed using a U-SPECT-II/CT system 
(MILabs, Utrecht, the Netherlands). Three normal mice were injected with 
45 MBq of 123I-IMZ by the tail vein. Whole-body SPECT images were acquired 
every 3 min from 15 to 60 min after injection under 2.0% isoflurane 
anesthesia. The images were reconstructed using ordered subset expectation 
maximization method with 16 subsets and six iterations including no scatter 
and attenuation correction. The voxel size was set to 0.8 × 0.8 × 0.8 mm. A 
Gaussian filter with 1.0 mm was applied for post-reconstruction smoothing 
filtering. Image display was per- formed using medical image data analysis 
software, AMIDE (version 1.0.2) [23]. The coronal images were displayed as 
maximum intensity projection. 
In biological distribution of normal mice, 125I-IMZ was prepared to a 
specific activity of 185 kBq/ml by addition of saline. A total of 18 fasted mice 
were administered 125I-IMZ by the tail vein (18.5 kBq/mouse). At 2, 5, 10, 30, 
60, and 120 min, three normal mice were, respectively, euthanized under 
isoflurane, and the following tissues were collected: blood, brain, thyroid, lung, 
heart, stomach, liver, gall bladder, small intestine, large intestine, kidney, and 
bladder. Tissues were weighed, and radioactivity was quantified using an 
automated γ-ray counter to calculate the percent injected dose (%ID) or 
percent injected dose per gram of tissue (%ID/g). 
Whole-body imaging and biological distribution in mice administered BNPP 
using 123/125I-IMZ  
Three mice were intraperitoneally injected with 100 mg/ kg BNPP. 
After 30 min of BNPP injection, 45 MBq of 123I-IMZ was injected by the tail 
vein. Whole-body SPECT images were acquired every 3 min from 15 to 60 min 
after 123I-IMZ injection under 2.0% isoflurane anesthesia. Reconstruction 
method was the same with normal mice study. 
In the biological distribution, a total of 18 mice were intraperitoneally 
injected with 50 or 100 mg/kg of BNPP at 30 min before injection of 125I-IMZ. 
At 30, 60, and 120 min after 125I-IMZ injection, three mice were, respectively, 
euthanized under isoflurane, and tissues were collected and quantified in the 
same manner as with the normal mice study. 
 
Metabolism of 123I-IMZ in vivo  
123I-IMZ was prepared to a specific activity of 30 MBq/ml by addition 
of saline. A total of 12 fasted mice were administered 123I-IMZ by the tail vein 
(3.7 MBq/mouse). At 10, 30, 60, and 120 min, three mice, respectively, were 
euthanized under isoflurane, and the following tissues were collected: blood, 
liver, gall bladder, and bladder. The metabolites present in each tissue were 
analyzed by TLC. Briefly, bile and urine were directly spotted onto a TLC 
plate, and heparin was added to 300 µl blood and centrifuged for 5 min at 18 
000g. Perchloric acid (30 µl) was added to the supernatant, which was 
centrifuged again, after which, the final supernatant was spotted onto the 
TLC plate as plasma. Krebs-Ringer phosphate buffer was added to the liver 
samples, followed by homogenization. Thereafter, ethanol was added to the 
homogenate to remove proteins, and the sample was centrifuged for 5 min at 
18 000g. The final supernatant was analyzed by TLC using 
chloroform/acetate/H2O at a ratio of 65 : 35 : 5 [22]. 
 
Statistical analysis  
Data were analyzed using Student’s t-test, and P values less than 0.01 
and 0.05 were considered statistically significant. 
Results  
Metabolism of 123I-IMZ in vitro  
We confirmed that the rates of flow (Rf) for 123I−, 123I-R- COOH, and 
123I-IMZ were in the ranges of 0.00–0.05, 0.40–0.50, and 0.95–1.00, 
respectively (Fig. 1). Figure 2 shows metabolite analyses of 123I-IMZ with and 
without BNPP. The fractional ratio of 123I-R-COOH decreased from 44 to 2%, 
whereas that of 123I-IMZ increased from 44 to 89%, depending on the BNPP 
concentration. Figure 3 shows metabolite analyses of 123I-IMZ with and 
without NADPH generator. With NADPH generator, we confirmed fractions 
of 123I-R-COOH, an unknown metabolite [metabolite 2 (M2)], 123I−, and 123I-
IMZ, whereas without NADPH generator, the only fraction not detected was 
M2. 
  
Whole-body imaging and biological distribution in normal mice using 123/125I-
IMZ  
Whole-body SPECT images were acquired using three normal mice, 
and similar images were obtained. Figure 4 shows whole-body images of a 
mouse at 15, 30, and 60 min after injection of 123I-IMZ. At 15 min after 
injection, 123I-IMZ primarily accumulated in the brain, liver, and kidney. At 
30 min, accumulation in the liver decreased, whereas accumulation in the 
thyroid and bladder increased. At 60 min, significant 123I-IMZ accumulation 
in the gall bladder, intestine, and bladder was noted. Table 1 shows the 
biological distribution in nor- mal mice using 125I-IMZ. Radioactivity in the 
lung, liver, kidney, and blood rapidly increased immediately after injection 
and then gradually decreased. In the thyroid, gall bladder, small intestine, 
and bladder, radioactivity gradually increased after injection. 
  
Whole-body imaging and biological distribution in mice administered BNPP 
using 123/125I-IMZ 
Figure 5 shows whole-body images of a mouse administered 100 
mg/kg BNPP at 15, 30, and 60 min after injection of 123I-IMZ. In three mice, 
similar whole-body images were obtained. At 15 min after injection, 123I-IMZ 
mainly accumulated in the brain and liver. At 30 min, accumulation in the 
liver slightly decreased, whereas accumulation in the intestine and bladder 
increased. At 60 min, 123I-IMZ gradually accumulated in the gall bladder and 
intestine. 
Table 2 shows the biological distribution in mice administered 50 or 
100 mg/kg BNPP at 30, 60, and 120 min after 125I-IMZ injection. 
Accumulation in the brain and liver significantly increased with 
administration of 100 mg/kg BNPP compared with normal mice at 30 min 
after 125I-IMZ injection, whereas accumulation in the thyroid, lung, heart, 
stomach, gall bladder, and small intestine significantly decreased. The effect 
of 100 mg/kg BNPP was greater than that of 50 mg/kg BNPP. Accumulation 
in the blood and urine was varied, com- pared with normal mice, because of 
the effect of BNPP. 
 
Metabolism of 123I-IMZ in vivo  
Figure 6a–d shows metabolite analyses in the plasma, liver, bile, and 
urine, respectively. In the plasma, fractions of 123I-R-COOH and 123I− were 
found. At 10 min after injection, 123I-IMZ was metabolized to 70% 123I-R-
COOH and 26% 123I−. The fractional ratio of 123I-R-COOH gradually decreased 
to 14% at 120 min after injection, whereas that of 123I− significantly increased 
to 77%. In the liver, we confirmed fractions of 123I-R- COOH, two unknown 
metabolites [metabolite 1 (M1) and M2], 123I−, and 123I-IMZ. The Rf values for 
M1 and M2 were in the ranges of 0.20–0.30 and 0.75–0.80, respectively. At 10 
min after injection, the fractional ratios of 123I-R-COOH, M1, M2, 123I−, and 
123I-IMZ were 72, 0.9, 3, 17, and 2%, respectively. The fractional ratios of 123I-
R-COOH and 123I-IMZ decreased to 24 and 4%, respectively, at 120 min after 
injection, whereas that of 123I− significantly increased to 60%. In the bile, the 
fractional ratios of 123I-R-COOH, M1, M2, 123I−, and 123I-IMZ were 70, 6, 0.8, 
14, and 3%, respectively, at 10 min after injection. The fractional ratios of 123I-
R-COOH and 123I-IMZ slightly decreased to 63 and 0%, respectively, at 120 
min after injection, whereas that of 123I− slightly increased to 25%. The other 
fractional ratios remained relatively unchanged. In the urine, the fractional 
ratios of 123I-R-COOH, M1, M2, 123I−, and 123I-IMZ were 84, 4, 0.6, 5, and 0%, 
respectively, at 10 min after injection. The fractional ratio of 123I-R-COOH 
slightly decreased to 78% at 120 min after injection, whereas that of 123I− 
slightly increased to 10%. The other fractional ratios remained relatively 
unchanged. 
 
Discussion  
Nuclear medicine imaging provides higher sensitivity and 
quantification capability to detect the activity of hepatic drug-metabolizing 
enzymes compared with other imaging techniques. Although 
radiopharmaceuticals are typically highly stable over time in vivo, our 
methodology indicates that they are almost fully metabolized in the liver, with 
metabolites accumulating in the excretory organs. Using this pathway for the 
metabolism of 123I-IMZ, which Yoshimura et al. [16] described, the present 
study investigated direct, noninvasive detection and quantification of the 
activity of hepatic drug-metabolizing enzymes using 123I-IMZ whole-body 
imaging. 
  
Metabolism of 123I-IMZ in vitro  
Although the metabolic pathway and the TLC Rf values of 123I-IMZ 
was previously reported [16,17], TLC Rf values for 123I-R-COOH-Glc and 123I-
R’-CH2COOH were not provided, and the authors could not detect the hepatic 
drug-metabolizing enzymes A and B (Supplementary Fig., Supplemental 
digital content 1, http://links.lww.com/NMC/A132). The TLC analyses of the 
present study demonstrated that 123I-IMZ was metabolized to 123I-R-COOH, 
123I−, and two unknown metabolites (M1 and M2). We then attempted to 
identify enzyme A (which converted 123I-IMZ to 123I-R-COOH) and enzyme B 
(which converted 123I-IMZ to M2). In the presence of BNPP, a specific and 
hepatic carboxylesterase inhibitor (Fig. 2), BNPP causes reduction of enzyme 
activity on hepatic carboxylesterase [21,24]. The fractional ratio of 123I-R-
COOH decreased depending on the concentration of BNPP, whereas the 
fractional ratio of 123I-IMZ increased, and other metabolites remained 
relatively unchanged. These results confirm that enzyme A is 
carboxylesterase. In the event of carboxylesterase dysfunction in the liver, 
production of 123I-R-COOH would be inadequate. Carboxylesterase plays an 
important role in the metabolism of ester-containing drugs and prodrugs [25] 
such as temocapril, angiotensin-converting- enzyme inhibitor [26], irinotecan, 
antitumor drugs [27], and cocaine-based narcotics [28]. Thus, it is an 
extremely important hepatic drug-metabolizing enzyme in humans. In the 
absence of NADPH generator to provide energy for CYP, M2 was not detected 
(Fig. 3). Therefore, we concluded that enzyme B, which converts 123I-IMZ to 
M2, was CYP. However, it appears that CYP plays a less significant role in 
the metabolism of 123I-IMZ than carboxylesterase, because only small 
amounts of M2 were detected in the analysis of in-vivo metabolism of 123I-IMZ 
(Fig. 3). Therefore, based on CYP dependence, we conclude that M2 is 123I-R′
-CH2COOH, and the remaining M1 would be 123I-R-COOH-Glc 
(Supplementary Fig., Supplemental digital content 1, 
http://links.lww.com/NMC/ A132). 
 
Whole-body imaging and biological distribution in normal mice using 123/125I-
IMZ 
To directly detect and quantify the activity of drug-metabolizing 
enzymes in metabolic drug clearance, it is necessary to image and quantify 
the accumulation of the enzymes in the excretory organ. In whole-body 
imaging (Fig. 4) and analyses of the biological distribution of 125I-IMZ (Table 
1), 123/125I-IMZ radioactivity was high in the blood, lung, liver (metabolic 
organ), and kidney (excretory organ) immediately after injection. This 
accumulation of radioactivity decreased over time. We can also confirm 
accumulation of radioactivity in the brain, the target organ of 123/125I-IMZ. By 
contrast, radioactivity in the thyroid, gall bladder, small intestine, and 
bladder increased over time. These data indicate that 123I-IMZ is excreted by 
enterohepatic and renal routes, as previously reported [17–19]. In addition, 
we found that 123/125I-IMZ is metabolized to 123/125I− based on accumulation in 
the thyroid; however, 123/125I− radioactivity in the thyroid was much lower 
than that in the gall bladder and bladder. 
 
Whole-body imaging and biological distribution in mice administered BNPP 
using 123/125I-IMZ 
Model mice with reduction of enzyme activity on carboxylesterase 
were produced by intraperitoneal BNPP injection. Changes in accumulation 
throughout the whole body were found in mice administered BNPP (Fig. 5 
and Table 2). Especially, the accumulation in the brain, gall bladder, intestine 
and bladder was lower than that of a normal mouse (Fig. 4), whereas the 
accumulation in the liver was higher than that of a normal mouse, although 
color scales were the same between a normal mouse and a mouse 
administered BNPP. 
In biological distribution, accumulation in the liver significantly 
increased depending on the concentration of BNPP compared with normal 
mice (Fig. 4 and Table 1), whereas accumulation in the gall bladder and small 
intestine significantly decreased at 30 and 60 min after 125I-IMZ injection. 
125I-IMZ accumulation in the gall bladder decreased by less than half in 
comparison with normal mice, whereas that in the liver increased by about 
two times in 50 and 100 mg/kg BNPP loading. BNPP is surmised to mainly 
inhibit hepatic carboxylesterase activity converting 125I-IMZ to 125I-R-COOH, 
although the BNPP-induced reduction in hepatic carboxylesterase activity 
should be evaluated by an enzyme assay with the appropriate substrate or 
western blot analysis. Furthermore, although we have to confirm the changes 
in metabolites of 125I-IMZ by TLC analysis, M2, 125I-IMZ and/or 125I– would 
accumulate in the gall bladder and small intestine in mice administered 
BNPP. The effect of BNPP can also be confirmed by the lower accumulation 
in the brain of mice administered BNPP compared with normal mice (Tables 
1 and 2), because BNPP would inhibit cerebral carboxylesterase activity. 
However, accumulation in the blood and urine was varied compared with 
normal mice, because blood and the bladder are susceptible to the effect of 
BNPP. Thus, if enzyme activity of hepatic carboxylesterase is reduced by 
hepatic dysfunction caused by some influence of medicine or diseases etc., in 
the clinical study, the 123I-IMZ imaging may provide evidence of higher 
accumulation in the liver and lower accumulation in the gall bladder and 
bladder for the direct measurement of the activity of hepatic carboxylesterase 
in comparison with healthy subjects. 
 
Metabolism of 123I-IMZ in vivo  
To directly detect and quantify the activity of drug-metabolizing 
enzymes in metabolic drug clearance, the radioactive metabolites of 123I-IMZ 
need to move from a metabolic organ to an excretory organ early. Figure 6a 
shows that the 123I-R-COOH and 123I− fractions were primarily found in the 
plasma. The fractional ratio of 123I-R-COOH gradually decreased over time, 
whereas that of 123I− increased, possibly because of deiodinase activity in the 
organs (e.g. liver and kidney). The fractions differed in the liver, bile, and 
urine. The fractions in the plasma could reflect whole-body conditions. 
Therefore, we believe that the results of TLC analyses of blood samples do not 
only reflect hepatic metabolites. In the liver (Fig. 6b), the fractional ratio of 
123I-R-COOH peaked immediately after injection. Over time, the fractional 
ratio of 123I-R-COOH decreased, whereas that of 123I− increased. Small 
amounts of other fractions (M1, M2, and 123I-IMZ) were also detected. Some 
of the metabolites in the liver shifted to bile in the gall bladder (Fig. 6c) and 
to urine in the bladder (Fig. 6d). In the bile and urine, the fractional ratios of 
all metabolites were similar and remained stable at all of the time points 
examined. In particular, 123I-R-COOH exhibited the highest fractional ratio 
(about 70% in the bile and 84% in the urine) of all metabolites. Other 
metabolites, including 123I−, exhibited significantly lower fractional ratios 
than 123I-R-COOH. Little or no administered 123I-IMZ was found in the bile 
and urine by enterohepatic and renal routes. With regard to hepatic 
carboxylesterase in the metabolic conversion of 123I-IMZ to 123I-R-COOH 
(Supplementary Fig., Supplemental digital content 1, 
http://links.lww.com/NMC/A132), the activity of hepatic carboxylesterase 
could be detected on the basis of accumulation of radioactivity in the gall 
bladder through the bile and the bladder through the urine in 123I-IMZ whole-
body imaging (Figs 4 and 5 and Tables 1 and 2). 
  
Limitations  
123I-IMZ whole-body imaging targeting the gall bladder or bladder 
may enable the measurement of individual variations in carboxylesterase 
activity. Following confirmation of the utility of 123I-IMZ whole-body imaging, 
our novel methodology should be evaluated in clinical studies after passing a 
clinical ethical review with the results of this study, although extreme care 
must be taken with regard to the number and types of metabolites examined, 
because Yoshimura et al. [15] suggested that there were slight differences in 
metabolites between animals and humans. For example, low levels of a 
hydrosis metabolite (123I-R′-OH) of 123I-IMZ have been detected in rats and 
rabbits, but not in mice or humans. Although we identified M2 as 123I-R′-
CH2COOH in this study, 123I-R′-OH may also be CYP dependent because of 
the hydrosis metabolite. However, this would not affect the identification of 
enzyme B (which converts 123I-IMZ to M2) as CYP. 
 
Conclusions  
As preliminary study for clinical application, 123I-IMZ whole-body 
imaging has good possibility of the direct measurement of the activity of 
hepatic carboxylesterase, which converted 123I-IMZ to 123I-R-COOH, as 
determined by the accumulation of 123I-R-COOH in the gall bladder and in 
the bladder. This novel 123I-IMZ whole- body imaging methodology might be 
useful in deter- mining the dosage of drugs to use in clinical individualized 
medicine. 
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Figure legends  
Fig. 1. Thin-layer chromatography analysis of radioactivity in plasma (a), 
liver (b), bile (c), and urine (d) samples. Samples were obtained from mice at 
10, 30, 60, and 120 min after 123I-Iomazenil (123I-IMZ) injection. Relative 
radioactivity was calculated by dividing the radioactive counts for each 
fraction by the total radioactivity. Rf values for 123/125I, 123/125I-R-COOH, and 
123/125I-IMZ were in the ranges of 0.00–0.05, 0.40–0.50, and 0.95–1.00, 
respectively. In addition, Rf values for other unknown metabolites [metabolite 
1 (M1) and metabolite 2 (M2)] were 0.20–0.30 and 0.75–0.80, respectively. 
 
Fig. 2. In-vitro analysis of metabolites of 123I-Iomazenil (123I-IMZ) with and 
without bis(4-nitrophenyl) phosphate (BNPP). The percent radioactivity of 
each sample was determined using mouse liver homogenate without BNPP (0 
µmol/l) or with 0.1, 1, 10, or 100 µmol/l BNPP. Error bars indicate the SD. 
  
Fig. 3. In-vitro analysis of metabolites of 123I-Iomazenil (123I-IMZ) with and 
without nicotinamide adenine dinucleo−tide phosphate (NADPH) generator. 
The percent radioactivity of each sample was determined using mouse liver 
homogenate with NADPH generator [NADPH (+ )] or without NADPH 
generator [NADPH ( )]. Error bars indicate the SD. 
 
Fig. 4. Whole-body images of a mouse obtained 15, 30, and 60 min after 45 
MBq 123I-Iomazenil (123I-IMZ) injection under 2.0% isoflurane anesthesia. 
Acquisition time was 3 min from the start time in each scan. 
  
Fig. 5 Whole-body images of a mouse administered 100 mg/kg bis(4-
nitrophenyl) phosphate obtained 15, 30, and 60 min after 45 MBq 123I-
Iomazenil (123I-IMZ) injection under 2.0% isoflurane anesthesia. Acquisition 
time was 3 min from the start time in each scan. 
 
Fig. 6. In-vivo analysis of three normal mice of metabolites in plasma (a), liver 
(b), bile (c), and urine (d). The percent radioactivity of each sample was 
determined from three mice at 10, 30, 60, and 120 min after 123I-Iomazenil 
(123I-IMZ) injection. Error bars indicate the SD. 
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Table.1
Organ Time (min)
2 5 10 30 60 120
Blood 6.82 ± 0.11 5.55 ± 0.58 4.27 ± 0.34 2.77 ± 0.14 1.85 ± 0.36 1.91 ± 0.20
Brain 3.95 ± 0.42 5.19 ± 1.15 4.40 ± 0.26 3.58 ± 0.41 2.10 ± 0.40 1.38 ± 0.06
Thyroid* 0.47 ± 0.13 0.55 ± 0.06 0.70 ± 0.12 1.53 ± 0.12 2.72 ± 0.47 3.60 ± 0.62
Lung 6.06 ± 0.27 5.11 ± 0.65 3.86 ± 0.34 2.31 ± 0.09 1.47 ± 0.29 1.46 ± 0.11
Heart 4.44 ± 0.19 3.73 ± 0.61 2.86 ± 0.23 1.96 ± 0.31 1.24 ± 0.19 1.21 ± 0.04
Stomach* 2.96 ± 0.59 5.06 ± 1.43 6.97 ± 0.31 11.86 ± 2.11 10.14 ± 1.95 8.32 ± 2.74
Liver 11.34 ± 1.76 11.30 ± 1.34 8.15 ± 0.82 3.16 ± 0.16 1.35 ± 0.37 1.20 ± 0.05
Gall bladder 4.75 ± 1.06 9.06 ± 5.59 9.09 ± 4.92 57.27 ± 6.59 76.69 ± 7.30 46.67 ± 3.56
Small intestine* 6.93 ± 0.44 8.24 ± 0.57 9.32 ± 1.09 12.79 ± 1.43 17.00 ± 3.56 10.50 ± 4.02
Large intestine* 2.34 ± 0.13 1.93 ± 0.05 1.68 ± 0.24 1.52 ± 0.23 1.09 ± 0.21 2.94 ± 3.23
Kidney 12.58 ± 1.76 11.61 ± 2.43 10.78 ± 5.07 6.07 ± 3.43 3.61 ± 2.17 5.02 ± 3.52
Urine* 0.78 ± 1.07 3.55 ± 3.11 10.99 ± 3.41 13.25 ± 9.37 32.43 ± 5.89 34.22 ± 3.28
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